Name | Number of supported studies | Average coverage | |
---|---|---|---|
retinal cone cell | 8 studies | 63% ± 24% | |
retinal rod cell | 6 studies | 47% ± 15% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
eye | 5 studies | 35% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 97% | 102.00 | 2566 / 2642 | 96% | 5.00 | 675 / 705 |
prostate | 100% | 87.35 | 244 / 245 | 88% | 2.16 | 442 / 502 |
breast | 99% | 87.44 | 456 / 459 | 79% | 2.39 | 881 / 1118 |
adrenal gland | 93% | 50.37 | 239 / 258 | 79% | 2.37 | 182 / 230 |
uterus | 100% | 139.64 | 170 / 170 | 70% | 1.87 | 320 / 459 |
lung | 98% | 64.12 | 569 / 578 | 63% | 1.61 | 728 / 1155 |
thymus | 98% | 61.68 | 639 / 653 | 62% | 1.81 | 377 / 605 |
bladder | 95% | 61.29 | 20 / 21 | 62% | 1.56 | 312 / 504 |
pancreas | 76% | 24.72 | 249 / 328 | 79% | 1.86 | 141 / 178 |
intestine | 99% | 70.05 | 953 / 966 | 52% | 1.07 | 273 / 527 |
liver | 94% | 51.35 | 213 / 226 | 56% | 1.25 | 228 / 406 |
kidney | 93% | 44.64 | 83 / 89 | 57% | 1.41 | 514 / 901 |
esophagus | 94% | 53.01 | 1362 / 1445 | 56% | 1.23 | 102 / 183 |
ovary | 100% | 137.79 | 180 / 180 | 50% | 1.12 | 213 / 430 |
skin | 91% | 84.62 | 1654 / 1809 | 56% | 1.52 | 266 / 472 |
stomach | 90% | 36.43 | 324 / 359 | 40% | 0.84 | 113 / 286 |
spleen | 100% | 111.99 | 240 / 241 | 0% | 0 | 0 / 0 |
adipose | 98% | 69.93 | 1176 / 1204 | 0% | 0 | 0 / 0 |
muscle | 97% | 67.32 | 782 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 96% | 54.49 | 1283 / 1335 | 0% | 0 | 0 / 0 |
heart | 95% | 48.51 | 820 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 77% | 35.05 | 712 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 69% | 1.55 | 20 / 29 |
eye | 0% | 0 | 0 / 0 | 64% | 12.80 | 51 / 80 |
tonsil | 0% | 0 | 0 / 0 | 51% | 1.07 | 23 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007168 | Biological process | receptor guanylyl cyclase signaling pathway |
GO_0007589 | Biological process | body fluid secretion |
GO_0007601 | Biological process | visual perception |
GO_0031282 | Biological process | regulation of guanylate cyclase activity |
GO_0007267 | Biological process | cell-cell signaling |
GO_0097381 | Cellular component | photoreceptor disc membrane |
GO_0001917 | Cellular component | photoreceptor inner segment |
GO_0120199 | Cellular component | cone photoreceptor outer segment |
GO_0005886 | Cellular component | plasma membrane |
GO_0005509 | Molecular function | calcium ion binding |
GO_0008048 | Molecular function | calcium sensitive guanylate cyclase activator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | GUCA1B |
Protein name | Guanylyl cyclase-activating protein 2 (GCAP 2) (Guanylate cyclase activator 1B) GUCA1B protein |
Synonyms | GCAP2 |
Description | FUNCTION: Stimulates two retinal guanylyl cyclases (GCs) GUCY2D and GUCY2F when free calcium ions concentration is low, and inhibits GUCY2D and GUCY2F when free calcium ions concentration is elevated (By similarity). This Ca(2+)-sensitive regulation of GCs is a key event in recovery of the dark state of rod photoreceptors following light exposure (By similarity). May be involved in cone photoreceptor response and recovery of response in bright light (By similarity). . |
Accessions | A4FUA1 Q9UMX6 ENST00000230361.4 |